Other Clinical Trial - Ruxolitinib Combined With Dexamethasone for HLH

Status Recruiting

Clinical Trial Summary

A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.

Clinical Trial Description

A modified protocol about ruxolitinib combined with dexamethasone which includes oral ruxolitinib (2.5 mg twice daily for patients if the age<14 years and the weight <25kg，5 mg twice daily for patients if the age<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and<18 years）. Dexamethasone (10mg/m2.d) delayes for the first 2 weeks （form week 1 to 2），(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8. Every 2 weeks, patients can be evaluated based the diagnosed index ;

Study Design

Related Conditions & MeSH terms

Hemophagocytic Lymphohistiocytosis
Lymphohistiocytosis, Hemophagocytic

Clinical Trial Details

NCT number	NCT03795909
Study type	Interventional
Source	Capital Research Institute of Pediatrics
Contact	Yan Yue, MD
Phone	8618515238169
Email	adaile123@sina.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 1, 2017
Completion date	March 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01652092` - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	N/A
Recruiting	`NCT02912702` - L-DEP as an Initial Treatment for EBV-HLH	Phase 3
Terminated	`NCT00176826` - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders	Phase 2/Phase 3
Not yet recruiting	`NCT06038422` - GTP Regimen in the Treatment of Refractory/Recurrent HLH	Phase 3
Completed	`NCT03510650` - Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
Completed	`NCT03259230` - Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Active, not recruiting	`NCT01494103` - Administration of Donor T Cells With the Caspase-9 Suicide Gene	Phase 1
Recruiting	`NCT05164978` - DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH	N/A
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Terminated	`NCT01547143` - Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis	N/A
Active, not recruiting	`NCT00006056` - Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders	N/A
Terminated	`NCT00006054` - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies	N/A
Recruiting	`NCT03533790` - DEP-Ru Regimen as a Salvage Therapy for HLH	Phase 3
Not yet recruiting	`NCT05315336` - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH	Phase 3
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting	`NCT04326348` - A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）	Phase 1
Recruiting	`NCT04551131` - Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis	Phase 1/Phase 2
Recruiting	`NCT05546060` - Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH	Phase 1
Recruiting	`NCT05137522` - Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH	N/A
Recruiting	`NCT04120090` - Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis	Phase 3